Alexandre Detappe | Nanomedicine Award | Young Scientist Award

Posted on by ScienceFather

Prof. Alexandre Detappe | Nanomedicine Award | Young Scientist Award

Prof. Alexandre Detappe, ICANS, France

Prof. Alexandre Detappe is a distinguished biophysicist and a leading figure in cancer research. Holding a PhD from the University of Lyon, France, he has contributed significantly to understanding and combating diseases like multiple myeloma and HER2+ breast cancer. Currently a Professor at Strasbourg Medical School, his research focuses on developing innovative drug delivery systems and small molecules to enhance immune responses against cancer. With extensive academic and institutional appointments, he co-founded several biotech companies, reflecting his commitment to translating research into practical solutions. Detappe’s multifaceted expertise and leadership in translational medicine make him a pivotal figure in advancing cancer therapeutics. 🧬🩺🔬

 

PUBLICATION PROFILE

Orcid

EDUCATION

Dr. Alexandre Detappe is a distinguished scholar in biophysics, with a rich educational background spanning renowned institutions in France. He earned his Bachelor’s degree in Physics and Science for Engineering from the University of Strasbourg in 2010. Subsequently, he pursued a Master’s degree in Medical Physics at the University of Grenoble, graduating in 2012. Dr. Detappe furthered his expertise with a Medical Physics residency at CEA Saclay in 2012-2013. His academic journey culminated in a PhD in Biophysics from the University of Lyon in 2017, followed by obtaining French authorization to supervise research from the University of Strasbourg in 2020. 🎓🔬

 

AWARDS

Dr. Alexandre Detappe’s groundbreaking contributions in biophysics and cancer research have garnered him numerous prestigious awards and fellowships. In 2021, he was honored with the Guy Ourisson Award by Cercle Gutenberg/University of Strasbourg, recognizing his outstanding achievements. His exceptional work also earned him the Brigitte Mérand Award from the Force Hémato Foundation in 2020 and the Brian D Novis Research Grant Award from the International Myeloma Foundation. Notably, his research excellence was acknowledged with the ASH Abstract Achievement Award in 2018 and the Marie Curie Award for the Best PhD in Radiation Oncology in 2016. Dr. Detappe’s accolades highlight his significant contributions to advancing medical science. 🏆🔬

 

RESEARCH FOCUS

Dr. Alexandre Detappe’s research spans various facets of cancer therapy and imaging, with a particular focus on leveraging nanotechnology for improved treatment outcomes. He explores innovative strategies such as nanoparticle-mediated drug delivery, image-guided radiation therapy, and molecular targeting. His work aims to enhance treatment efficacy while minimizing side effects, particularly in cancers like multiple myeloma and breast cancer. Through a multidisciplinary approach integrating biophysics, molecular biology, and nanomedicine, Dr. Detappe pioneers advancements in precision medicine, striving to make cancer therapies more effective and accessible. 🧬⚗️🔬

 

PUBLICATION TOP NOTES

Subcutaneous Administration of a Zwitterionic Chitosan-Based Hydrogel for Controlled Spatiotemporal Release of Monoclonal Antibodies.

Influence of pneumatic transportation on the stability of monoclonal antibodies.

Site-Selective Protein Conjugation by a Multicomponent Ugi Reaction.

An autoinhibited state of 53BP1 revealed by small molecule antagonists and protein engineering

Molecular bottlebrush prodrugs as mono- and triplex combination therapies for multiple myeloma.

Clinically Translatable Transcrocetin Delivery Platform for Correction of Tumor Hypoxia and Enhancement of Radiation Therapy Effects.

A Combination of Native LC-MS Approaches for the Comprehensive Characterization of the Antibody-Drug Conjugate Trastuzumab Deruxtecan.

Optimal Physicochemical Properties of Antibody–Nanoparticle Conjugates for Improved Tumor Targeting

Anti‐BCMA Immuno‐NanoPET Radiotracers for Improved Detection of Multiple Myeloma

Liposomal encapsulation of trans-crocetin enhances oxygenation in patients with COVID-19-related ARDS receiving mechanical ventilation